M 033
Alternative Names: Lenti-GalC-S1S3; M-033Latest Information Update: 18 Jul 2025
At a glance
- Originator M6P Therapeutics
- Class Gene therapies
- Mechanism of Action Galactosylceramidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Globoid cell leukodystrophy
Most Recent Events
- 18 Jul 2025 M 033 is still in early research development in Globoid-cell-leukodystrophy in USA (Parenteral) (M6P Therapeutics pipeline, July 2025)
- 28 Mar 2025 No recent reports of development identified for early research development in Globoid-cell-leukodystrophy in USA (Parenteral)
- 09 Feb 2023 M 033 receives Rare pediatric drug for Enzyme replacement therapy status for in USA prior to February 2023 (M6P Therapeutics website, February 2023)